- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - IND APPROVAL BY U.S. FDA FOR MRNA MPOX VACCINE | 1 | HKEx | ||
| 26.02. | AB&B BIO-TECH-B (02627): PROFIT ALERT - EXPECTED REDUCTION IN LOSS | 2 | HKEx | ||
| 16.02. | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - INCLUSION AS A CONSTITUENT OF HANG SENG COMPOSITE INDEX | 3 | HKEx | ||
| 30.01. | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - APPROVAL OF OUR APPLICATION FOR TRIVALENT SUBUNIT INFLUENZA VACCINE BY THE NMPA | - | HKEx | ||
| AB&B BIO-TECH Aktie jetzt für 0€ handeln | |||||
| 12.01. | AB&B BIO-TECH-B (02627): (1) RESIGNATION OF NON-EXECUTIVE DIRECTOR; AND (2) RESIGNATION OF BOARD SECRETARY AND JOINT COMPANY SECRETARY | - | HKEx | ||
| 23.12.25 | AB&B BIO-TECH-B (02627): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 23.12.25 | AB&B BIO-TECH-B (02627): (1) POLL RESULTS OF THE SECOND EXTRAORDINARY GENERAL MEETING OF 2025 (2) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND ... | 1 | HKEx | ||
| 08.12.25 | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - COMMENCEMENT OF PHASE III CLINICAL TRIAL FOR LYOPHILIZED HUMAN RABIES VACCINE (HUMAN DIPLOID CELL) | 1 | HKEx | ||
| 04.12.25 | AB&B BIO-TECH-B (02627): FORM OF PROXY FOR THE SECOND EXTRAORDINARY GENERAL MEETING OF 2025 TO BE HELD ON TUESDAY, DECEMBER 23, 2025 AND ANY ADJOURNMENT ... | 1 | HKEx | ||
| 04.12.25 | AB&B BIO-TECH-B (02627): (1) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR (2) RE-APPOINTMENT OF AUDITORS AND (3) NOTICE OF EGM | 4 | HKEx | ||
| 04.12.25 | AB&B BIO-TECH-B (02627): NOTICE OF THE SECOND EXTRAORDINARY GENERAL MEETING OF 2025 | - | HKEx | ||
| 04.12.25 | AB&B BIO-TECH-B (02627): (I) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR; (II) NOMINATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND (III) CHANGE ... | 1 | HKEx | ||
| 13.11.25 | AB&B BIO-TECH-B (02627): VOLUNTARY ANNOUNCEMENT - COMMENCEMENT OF PHASE I CLINICAL TRIAL FOR ADJUVANTED QUADRIVALENT SUBUNIT INFLUENZA VACCINE AND ADJUVANTED ... | 1 | HKEx | ||
| 15.10.25 | AB&B BIO-TECH-B (02627): INSIDE INFORMATION - APPLICATION FOR THE H SHARE FULL CIRCULATION BY THE COMPANY | - | HKEx | ||
| 29.09.25 | AB&B BIO-TECH-B (02627): NOTIFICATION LETTER TO NON-REGISTERED HOLDERS OF H SHARES AND REQUEST FORM - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE ... | - | HKEx | ||
| 29.09.25 | AB&B BIO-TECH-B (02627): NOTIFICATION LETTER TO REGISTERED H SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | 1 | HKEx | ||
| 29.09.25 | AB&B BIO-TECH-B (02627): 2025 INTERIM REPORT | - | HKEx |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,550 | -0,80 % | Shortseller-Positionen aktuell: Auto1, Energiekontor, freenet, Gerresheimer, Puma, Qiagen, TeamViewer | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| TANGO THERAPEUTICS | 16,820 | 0,00 % | Erasca, Inc.: Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat | ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO... ► Artikel lesen | |
| BIONTECH | 87,65 | -1,74 % | Revolution in der Krebstherapie: Vidac Pharma attackiert den Krebs-Thron der Großen! Warum der kleinere Mitbewerber Riesen wie Bayer und BioNTech die Show stehlen könnte! | Die Welt der Biotechnologie und Pharmazie ist aktuell in Aufruhr, denn technologische Durchbrüche und strategische Neuausrichtungen versprechen eine spannende Zukunft für Anleger. Besonders im Fokus... ► Artikel lesen | |
| ARCELLX | 114,36 | +0,09 % | Weekly Buzz: MGNX's LINNET Trial On Hold; Eton Pharmaceuticals, ALUR Get FDA Nod; GILD Snaps Up ACLX | FOSTER CITY (dpa-AFX) - This week, the biotech space witnessed significant milestones, including FDA approvals, oncology drug acquisitions, and collaborations. Positive clinical trial results... ► Artikel lesen | |
| MODERNA | 46,500 | -6,38 % | Moderna: Kombi-Impfung für Grippe und Covid erhält Zulassung | Gute Nachrichten für Moderna: Die EU-Arzneimittelbehörde EMA hat grünes Licht gegeben für den ersten Kombi-Impfstoff gegen Corona und Grippe. Der Wirkstoff solle für Menschen ab 50 Jahren zugelassen... ► Artikel lesen | |
| ERASCA | 15,560 | +2,91 % | Clear Street raises Erasca stock price target on combination trial deal | ||
| TYRA BIOSCIENCES | 34,550 | -1,96 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| CG ONCOLOGY | 60,35 | -1,87 % | CG Oncology Inc.: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 70,96 | -1,79 % | RBC Capital lowers Apogee Therapeutics stock price target on dosing outlook | ||
| ADMA BIOLOGICS | 15,700 | -5,11 % | ADMA Biologics Announces $200 Mln Capital Return Plan | ||
| EVOTEC | 5,464 | -3,33 % | Shortseller-Positionen aktuell: Evotec, Gerresheimer, HelloFresh, Renk, Hypoport, Symrise, TUI | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,520 | 0,00 % | Beam Therapeutics Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 37,450 | +1,03 % | Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | Bezuclastinib mean TSS reduction deepens to -32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 28,510 | -0,31 % | UBS cuts Harmony Biosciences stock price target on earlier Wakix generic entry | ||
| MINERALYS THERAPEUTICS | 26,700 | -7,29 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen |
AB&B BIO-TECH CO LTD JS gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AB&B BIO-TECH CO LTD JS finden Sie auf Wallstreet Online.